RxDoctor Payments Data

Daniel Deem, MD

Internal Medicine · Mahomet, ILNPI 1487948386

Payments from drug & device makers

$1,330in general payments, 2019–2025

Across 83 payments — averaging $16.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$589
  • Pfizer$173
  • Novo Nordisk$130
  • AbbVie$66
  • AstraZeneca$64
  • Lilly USA, LLC$49
  • plus $260 from 11 others

What the payments were for

  • Food & beverage$1,330100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,330 in reported general payments places this provider in the 80th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$241,345
Medicare patients
315
Services billed
17,830

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide283$308,046
EliquisApixaban186$229,256
JardianceEmpagliflozin158$201,441
TrulicityDulaglutide96$103,646
XareltoRivaroxaban55$73,591
EntrestoSacubitril/Valsartan43$62,275
MounjaroTirzepatide47$61,810
Trelegy ElliptaFluticasone/Umeclidin/Vilanter74$53,051
FarxigaDapagliflozin Propanediol33$32,867
DescovyEmtricitabine/Tenofov Alafenam12$25,999
Repatha SureclickEvolocumab41$25,606
TradjentaLinagliptin16$11,543
RybelsusSemaglutide12$11,424
Atorvastatin Calcium851$11,140
Victoza 3-PakLiraglutide12$8,664

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$130$319,470295 claims
PfizerEliquis$173$229,256186 claims
Boehringer IngelheimJardiance, Tradjenta$17$212,983174 claims
Lilly USA, LLCTrulicity, Mounjaro$49$165,456143 claims
Johnson & JohnsonXarelto$16$73,59155 claims
AstraZenecaFarxiga$64$32,86733 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Mahomet

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →